Editorial Videos

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.

In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.

In an interview with ACT Editor Andy Studna, Jim Reilly, VP, R&D Strategies, Veeva Systems, discusses improving collaborations with research sites and provides an outlook of how the new year looks for clinical trials.

In an interview with ACT Associate Editor Don Tracy, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, provides her thoughts on the success of the trial.

In an interview with ACT editor Andy Studna, Jim Reilly, VP, R&D Strategy, Veeva Systems, discusses ways stakeholders can select the best solutions available in clinical trials.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses the Summit for Clinical Ops Executives (SCOPE) conferences in Europe and the US.

In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and how the need to create it came about.

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene discusses their new study 'Reshaping Pharmacovigilance in the Age of AI'

In an interview with ACT editor, Andy Studna, Hesterlee, Chief Research Officer at the Muscular Dystrophy Association discusses a new therapy for Duchenne Muscular Dystrophy, Vamorolone, and what sets it apart from other therapies in the market.

New pre-competitive, disease-agnostic Consortium hopes to optimize advocacy group-industry collaboration to ultimately accelerate the pace of medicines development.

Slope.io CEO Rust Felix Discusses Phase I/II Oncology Sample Management Using Logistical Workflows

Inato Chief Strategy Officer Liz Beatty Discusses Sites that Want to Participate

Anca Copaescu, Founder and CEO of Strategikon Pharma Discusses Clinical Solutions for the Business Operations Side of Clinical Trials

Rob Bohacs, Chief Solutions Officer and Founder, ClinOne Discusses HCP and Patient Clinical Trials Recruitment

Lucille Coassin, Sr. Dir Pharma Partnerships, Current Health Discusses Connected Device Patient Monitoring